European committee upholds negative opinion of Folotyn

Allos Therapeutics, developers of Folotyn (pralatrexate injection), announced some bad news from European regulators.

Allos had requested that the European Medicines Agency's Committee For Medicinal Products for Human Use (CHMP) to reconsider and re-examine its negative opinion on the company's seeking marketing authorization application (MAA) for Folotyn in Europe as a treatment for patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

Hoping they would change their minds and therefore their opinion, Allos was disappointed to be told that after reconsideration, the CHMP merely confirmed its previous negative opinion on the drug.

"We are very disappointed with the CHMP opinion on the MAA for Folotyn in Europe," said Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics. "We will continue to ... pursue regulatory approval to market Folotyn for relapsed or refractory PTCL in other countries, and to evaluate our options for bringing Folotyn to patients who could benefit from it in Europe. We also remain fully committed to advancing the Folotyn development program in hematologic malignancies, including first-line PTCL and relapsed or refractory cutaneous T-cell lymphoma."

Folotyn was given accelerated approval by the US FDA in 2009 as a single-agent for the treatment of relapsed or refractory PTCL.

Allos was recently acquired through merger by Spectrum Pharmaceuticals, makers of Zevalin, a treatment for indolent non-Hodgkin's lymphomas.

Source: MarketWatch

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap